LEADER 04232nam 22006855 450 001 9910502589503321 005 20251113195606.0 010 $a3-030-39330-5 024 7 $a10.1007/978-3-030-39330-4 035 $a(CKB)5100000000044201 035 $a(MiAaPQ)EBC6768753 035 $a(Au-PeEL)EBL6768753 035 $a(OCoLC)1280404056 035 $a(DE-He213)978-3-030-39330-4 035 $a(EXLCZ)995100000000044201 100 $a20211013d2021 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBehavioral Clinical Trials for Chronic Diseases $eScientific Foundations /$fby Lynda H. Powell, Kenneth E. Freedland, Peter G. Kaufmann 205 $a1st ed. 2021. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021. 215 $a1 online resource (324 pages) 225 1 $aBehavioral Science and Psychology Series 311 08$a3-030-39328-3 327 $aIntroduction: the window of opportunity -- A selected history of randomized behavioral clinical trials: what we learned -- A clinically significant problem and a clincially significant benefit -- The process of developing a behavioral treatment for chronic disease -- The hypothesized pathway from behavioral treatment to chronic disease -- Equipoise, blinding, and investigator discipline -- Sensitivity to diversity -- Protection of randomization -- Choice of appropriate control group -- Readiness to conduct a behavioral randomized clinical trial -- Concluding remarks. 330 $aThis is the first comprehensive guide to the design of behavioral randomized clinical trials (RCT) for chronic diseases. It includes the scientific foundations for behavioral trial methods, problems that have been encountered in past behavioral trials, advances in design that have evolved, and promising trends and opportunities for the future. The value of this book lies in its potential to foster an ability to ?speak the language of medicine? through the conduct of high-quality behavioral clinical trials that match the rigor commonly seen in double-blind drug trials. It is relevant for testing any treatment aimed at improving a behavioral, social, psychosocial, environmental, or policy-level risk factor for a chronic disease including, for example, obesity, sedentary behavior, adherence to treatment, psychosocial stress, food deserts, and fragmented care. Outcomes of interest are those that are of clinical significance in the treatment of chronic diseases, including standard risk factors such as cholesterol, blood pressure, and glucose, and clinical outcomes such as hospitalizations, functional limitations, excess morbidity, quality of life, and mortality. This link between behavior and chronic disease requires innovative clinical trial methods not only from the behavioral sciences but also from medicine, epidemiology, and biostatistics. This integration does not exist in any current book, or in any training program, in either the behavioral sciences or medicine. 410 0$aBehavioral Science and Psychology Series 606 $aClinical health psychology 606 $aMedicine, Preventive 606 $aHealth promotion 606 $aAlternative medicine 606 $aTherapeutics 606 $aHealth Psychology 606 $aHealth Promotion and Disease Prevention 606 $aComplementary and Alternative Medicine 606 $aTherapeutics 615 0$aClinical health psychology. 615 0$aMedicine, Preventive. 615 0$aHealth promotion. 615 0$aAlternative medicine. 615 0$aTherapeutics. 615 14$aHealth Psychology. 615 24$aHealth Promotion and Disease Prevention. 615 24$aComplementary and Alternative Medicine. 615 24$aTherapeutics. 676 $a616.044 676 $a616.044 700 $aPowell$b Lynda H.$01071363 702 $aKaufmann$b Peter G. 702 $aFreedland$b Kenneth E. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910502589503321 996 $aBehavioral clinical trials for chronic diseases$92566907 997 $aUNINA